Innoviva Free Cash Flow 2010-2023 | INVA
Innoviva free cash flow from 2010 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Innoviva Annual Free Cash Flow |
| 2023 |
140.65 |
| 2022 |
201.66 |
| 2021 |
363.81 |
| 2020 |
313.10 |
| 2019 |
257.45 |
| 2018 |
223.53 |
| 2017 |
141.75 |
| 2016 |
60.71 |
| 2015 |
10.12 |
| 2014 |
-266.41 |
| 2013 |
-217.34 |
| 2012 |
-130.10 |
| 2011 |
-91.97 |
| 2010 |
-75.99 |
| 2009 |
-58.81 |
| Innoviva Quarterly Free Cash Flow |
| 2023-12-31 |
140.65 |
| 2023-09-30 |
107.55 |
| 2023-06-30 |
63.83 |
| 2023-03-31 |
25.65 |
| 2022-12-31 |
201.66 |
| 2022-09-30 |
192.79 |
| 2022-06-30 |
177.12 |
| 2022-03-31 |
98.09 |
| 2021-12-31 |
363.81 |
| 2021-09-30 |
265.43 |
| 2021-06-30 |
168.72 |
| 2021-03-31 |
84.11 |
| 2020-12-31 |
313.10 |
| 2020-09-30 |
227.82 |
| 2020-06-30 |
153.26 |
| 2020-03-31 |
73.47 |
| 2019-12-31 |
257.45 |
| 2019-09-30 |
190.55 |
| 2019-06-30 |
133.15 |
| 2019-03-31 |
76.66 |
| 2018-12-31 |
223.53 |
| 2018-09-30 |
161.75 |
| 2018-06-30 |
101.64 |
| 2018-03-31 |
49.91 |
| 2017-12-31 |
141.75 |
| 2017-09-30 |
93.89 |
| 2017-06-30 |
50.40 |
| 2017-03-31 |
27.76 |
| 2016-12-31 |
60.71 |
| 2016-09-30 |
39.65 |
| 2016-06-30 |
19.70 |
| 2016-03-31 |
7.25 |
| 2015-12-31 |
10.12 |
| 2015-09-30 |
3.21 |
| 2015-06-30 |
0.55 |
| 2015-03-31 |
-1.62 |
| 2014-12-31 |
-266.41 |
| 2014-09-30 |
-126.67 |
| 2014-06-30 |
-105.60 |
| 2014-03-31 |
-107.26 |
| 2013-12-31 |
-217.34 |
| 2013-09-30 |
-91.30 |
| 2013-06-30 |
-49.75 |
| 2013-03-31 |
-32.37 |
| 2012-12-31 |
-130.10 |
| 2012-09-30 |
-105.59 |
| 2012-06-30 |
-77.46 |
| 2012-03-31 |
-42.43 |
| 2011-12-31 |
-91.97 |
| 2011-09-30 |
-65.71 |
| 2011-06-30 |
-46.41 |
| 2011-03-31 |
-27.27 |
| 2010-12-31 |
-75.99 |
| 2010-09-30 |
-60.36 |
| 2010-06-30 |
-41.02 |
| 2010-03-31 |
-23.64 |
| 2009-12-31 |
-58.81 |
| 2009-09-30 |
-56.31 |
| 2009-06-30 |
-33.67 |
| 2009-03-31 |
-26.83 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.024B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
